No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Dan Shochat?

Dr. Dan Shochat


Agama Inc. (Consultants)

Direct Phone: (650) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Agama Inc. (Consultants)

Background Information

Employment History

Agenix Limited





Consulting Vice President of Development

Intellect Neurosciences Inc

Group Director, Product Research and Development

Immunomedics , Inc.

Director of Biotechnology Development

American Cyanamid Company

Senior Vice President and Chief Scientific Officer

Coulter Pharmaceutical , Inc.

Vice President of Pharmaceutical Development

Deltagen , Inc.

Visiting Lecturer and Adjunct Professor At the Chemistry Department

Rutgers University


Celscia Therapeutics Inc.

Scientific Advisory Board Member
PROLOR Biotech , Inc.

Member of the Technical Advisory Committee To the Board of Directors

Associate Member
University of Medicine and Dentistry of New Jersey

Center for Molecular Medicine and Immunology

Biotechnology Development Section

Scientific Advisory Board Member
Modigene Inc.

Scientific Advisory Board Member
Mindset BioPharmaceuticals Inc


Bachelor of Science


Hebrew University

Master in Science


Hebrew University



L.S.U. Medical School



Louisiana State University Medical Center

Web References (30 Total References)

Life Sciences News Headlines - ADC Review / Journal of Antibody-drug Conjugates [cached]

Intellect's program is led by Dan Shochat, Ph.D., Intellect Neurosciences' Consulting Vice President of Development and a pioneer in the development of antibody drug conjugates for cancer treatments.

About AMD :: Intellect Neurosciences, Inc [cached]

IN-N01-OX2 development is being led by Dan Shochat, Ph.D., Consulting Vice President Development, an internationally recognized leader in the development of antibody products. Dr. Shochat led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co. and in collaboration with Celltech, Dr. Shochat led the development of the first approved antibody-drug conjugate, Mylotarg®. He also invented the technology and single-vial formulation and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. With Dr. Shochat's expert assistance, Intellect has developed a detailed road-map for IN-N01-OX2 development to lead to the first clinical trials being initiated by the end of 2014.

David Pritchard | KaloBios Pharmaceuticals | Email CEO CFO [cached]

Dan Shochat VP Non-clinical Development

Management Team :: Intellect Neurosciences, Inc [cached]

Dan Shochat, Ph.D. Vice President

Dan Shochat, Ph.D. has more than 28 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. Prior to joining Intellect, he served as vice president of nonclinical development at KaloBios Therapeutics. Prior, he was among the first employees of Immunomedics Inc., Newark, NJ where he served as group director, product R&D. Dr. Shochat is the inventor of several technologies, including that of the approved in vivo tumor-imaging agent CEA-Scan; Mylotarg - the first approved antibody-cytotoxic drug conjugate; and the design, process and formulation for the commercial radiolabeling of the B1 antibody at a 55 Curie scale. The lead product from this work was Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA on June 2003. He is co-founder of Celscia Therapeutics Inc. - a therapeutic antibodies development company - which merged with KaloBios Therapeutics in January 2004.
From 2001 to 2007 Dr. Shochat was a member of the Technical Advisory Committee to the Board of Directors of the Australian Nuclear Science and Technology Organization. He also serves as consultant and member of scientific advisory boards of several biopharmaceutical companies and venture capital funds.
Dr. Shochat earned B.Sc. in Zoology and Physiology (1965) and M.Sc. in Physiology (1968) from the Hebrew University of Jerusalem, Israel and Ph.D. in Biochemistry and Protein Chemistry (1976) from LSU Medical Center, New Orleans, LA. He was a post-doctoral fellow in the Department of Biochemistry (1975-1978) and Sr. Research Associate at the Division of Experimental Pathology (1978-1983), the University of Kentucky Medical Center, Lexington, KY. In 1983 he participated in founding the Center for Molecular Medicine and Immunology at the University of Medicine and Dentistry of New Jersey, Newark, NJ, where he was an Associate Member until he joint Immunomedics, Inc. in 1984. From 1986-1992 Dr. Shochat served successively as visiting lecturer and adjunct professor at the Chemistry Department of Rutgers University Graduate School (Newark, NJ campus).

News for Friday, 10 August 2012 - [cached]


Similar Profiles

Other People with this Name

Other people with the name Shochat

Ilan Shochat

Sharon Shochat
The Henry Jackson Society Inc

Eden Shochat
Capital On Stage

Elisheva Shochat
Philips Electronics India Limited

Hadar Shochat
MindU Ltd

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory